[go: up one dir, main page]

EE05026B1 - Fulvestrandi kasutamine resistentse rinnav„hi ravis - Google Patents

Fulvestrandi kasutamine resistentse rinnav„hi ravis

Info

Publication number
EE05026B1
EE05026B1 EEP200200574A EEP200200574A EE05026B1 EE 05026 B1 EE05026 B1 EE 05026B1 EE P200200574 A EEP200200574 A EE P200200574A EE P200200574 A EEP200200574 A EE P200200574A EE 05026 B1 EE05026 B1 EE 05026B1
Authority
EE
Estonia
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
EEP200200574A
Other languages
English (en)
Estonian (et)
Inventor
Thurlimann Beat
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05026(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200574A publication Critical patent/EE200200574A/xx
Publication of EE05026B1 publication Critical patent/EE05026B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200574A 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis EE05026B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (fr) 2000-04-05 2001-04-02 Utilisation de fulvestrant dans le traitement du cancer resistant du sein

Publications (2)

Publication Number Publication Date
EE200200574A EE200200574A (et) 2004-04-15
EE05026B1 true EE05026B1 (et) 2008-06-16

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200574A EE05026B1 (et) 2000-04-05 2001-04-02 Fulvestrandi kasutamine resistentse rinnav„hi ravis

Country Status (28)

Country Link
US (2) US20030158166A1 (fr)
EP (2) EP1272195B1 (fr)
JP (1) JP2003528919A (fr)
KR (1) KR100757764B1 (fr)
CN (1) CN1431905A (fr)
AT (1) ATE306270T1 (fr)
AU (2) AU4437201A (fr)
BR (1) BR0109789A (fr)
CA (1) CA2403608A1 (fr)
CH (1) CH1272195H1 (fr)
CZ (1) CZ303096B6 (fr)
DE (1) DE60113975T2 (fr)
DK (1) DK1272195T3 (fr)
EE (1) EE05026B1 (fr)
ES (1) ES2248300T3 (fr)
GB (1) GB0008172D0 (fr)
HU (1) HU230064B1 (fr)
IL (2) IL151932A0 (fr)
IS (1) IS2869B (fr)
MX (1) MXPA02009744A (fr)
NO (1) NO329949B1 (fr)
NZ (1) NZ539603A (fr)
PL (1) PL201175B1 (fr)
RU (1) RU2265438C2 (fr)
SK (1) SK287779B6 (fr)
UA (1) UA80388C2 (fr)
WO (1) WO2001074366A1 (fr)
ZA (1) ZA200207538B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (fr) * 2004-07-09 2006-02-08 Proskelia SAS Combinaisons d'antisetrogène et d'inhibteurs de l'aromatase
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
CA2628747C (fr) * 2005-11-22 2014-01-21 Incyte Corporation Combinaisons d'agents de therapie hormonale et inhibiteurs de metalloprotease pour le traitement du cancer
WO2007143600A2 (fr) * 2006-06-05 2007-12-13 Incyte Corporation Inhibiteurs de la sheddase combinés avec des substances immunothérapeutiques se liant à cd30 destinés au traitement de maladies associées à cd30
WO2012154809A1 (fr) * 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions et procédés pour le traitement du cancer
US9029582B2 (en) 2011-05-20 2015-05-12 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
EP3092027A4 (fr) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Procédés et compositions transpapillaires pour le dignostic et le traitement de maladies du sein
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CA3073836A1 (fr) 2017-09-11 2019-03-14 Atossa Therapeutics, Inc. Procedes pour la fabrication et l'utilisation d'endoxifene
AU2019274815B2 (en) * 2018-05-24 2024-11-07 Shivanka Research LLC Prodrugs of fulvestrant
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
EP4110344A4 (fr) * 2020-02-29 2024-03-13 The University Of Vermont Utilisation de thyromimétiques pour le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
CN1431905A (zh) 2003-07-23
NO20024735L (no) 2002-11-27
IS2869B (is) 2014-03-15
NZ539603A (en) 2008-02-29
JP2003528919A (ja) 2003-09-30
ZA200207538B (en) 2003-12-19
CZ20023309A3 (cs) 2003-02-12
PL357936A1 (en) 2004-08-09
NO20024735D0 (no) 2002-10-02
AU2001244372B2 (en) 2006-02-16
RU2265438C2 (ru) 2005-12-10
HUP0300339A3 (en) 2009-01-28
WO2001074366A1 (fr) 2001-10-11
HK1051498A1 (en) 2003-08-08
SK14292002A3 (sk) 2003-08-05
ES2248300T3 (es) 2006-03-16
EP1272195B1 (fr) 2005-10-12
ATE306270T1 (de) 2005-10-15
HU230064B1 (hu) 2015-06-29
KR20030007501A (ko) 2003-01-23
CA2403608A1 (fr) 2001-10-11
NO329949B1 (no) 2011-01-31
DE60113975D1 (de) 2006-02-23
DK1272195T3 (da) 2006-01-16
DE60113975T2 (de) 2006-06-22
UA80388C2 (en) 2007-09-25
AU4437201A (en) 2001-10-15
BR0109789A (pt) 2003-01-21
IL151932A (en) 2007-07-04
EP1272195A1 (fr) 2003-01-08
HUP0300339A2 (hu) 2003-06-28
US20110183949A1 (en) 2011-07-28
EP1586323A1 (fr) 2005-10-19
PL201175B1 (pl) 2009-03-31
US20030158166A1 (en) 2003-08-21
GB0008172D0 (en) 2000-05-24
IL151932A0 (en) 2003-04-10
MXPA02009744A (es) 2004-02-26
CH1272195H1 (fr) 2019-10-15
IS6576A (is) 2002-10-01
SK287779B6 (sk) 2011-09-05
KR100757764B1 (ko) 2007-09-12
CZ303096B6 (cs) 2012-04-04
EE200200574A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
EE200200574A (et) Fulvestrandi kasutamine resistentse rinnavähi ravis
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
FR08C0013I2 (fr) Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
MY138883A (en) Use of asiatic acid for treatment of cencer
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60223576D1 (de) Hautbehandlungszusammensetzung
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
DE60107034D1 (de) Misch- und Ladeöffnung zur medizinischen Behandlung
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
PL366066A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka sutka
MY140723A (en) Method of treatment
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20005548L (no) Mykobakterieinhibitorer
EP1684795A4 (fr) Procedes et agents pour le traitement du cancer
NO20010630D0 (no) Krummet trapp og trappetrinn for krummet trapp
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231